Your session is about to expire
← Back to Search
Pembrolizumab + Other Agents for Melanoma
Study Summary
This trial is testing new treatments for melanoma, specifically to see if they are safe and more effective than current options.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a live vaccine in the last 30 days.I have an immune system disorder or have been on immune-weakening medication recently.I am not pregnant or breastfeeding, and if I can have children, I use effective birth control or practice abstinence.My cancer has spread to my brain or the membranes around my brain.My organs are functioning well.I have previously been treated with TVEC or other virus-based cancer therapies.My cancer is only present in the mucosal areas.My melanoma diagnosis was confirmed through lab tests.My melanoma is at a stage where surgery is possible.I have had radiation therapy for my melanoma.I have not had major surgery within the last 3 weeks.I have received a transplant from another person.I am a male willing to use contraception or abstain from sex while taking gebasaxturev and for 120 days after.My side effects from previous treatments are mild, except for hair loss.I have an autoimmune disease treated with medication in the last 2 years.I am currently being treated for an infection.I am a male willing to use contraception or abstain from sex while on ATRA and for 7 days after.I have another cancer that is getting worse or needed treatment in the last 2 years.I have a history of hepatitis B.I have had pneumonitis that was not caused by an infection.I have had active tuberculosis in the past.I have not had cancer treatment in the last 4 weeks.My melanoma is in the eye or mucous membranes.You have had a serious allergic reaction to a different monoclonal antibody treatment in the past.I had radiotherapy less than 2 weeks before starting the study treatment.I have not received treatment for my Stage IIIB, IIIC, or IIID melanoma.I had surgery to remove my melanoma.You have already given a sample of your tumor for testing before the study starts.I have a known history of HIV.
- Group 1: Favezelimab + Pembrolizumab
- Group 2: Pembrolizumab + Vibostolimab
- Group 3: Pembrolizumab + Gebasaxturev
- Group 4: Pembrolizumab
- Group 5: Pembrolizumab + all-trans retinoic acid (ATRA)
- Group 6: Pembrolizumab + MK-4830
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the standard dosage of Pembrolizumab for most patients?
"Pembrolizumab is most commonly used to treat malignant neoplasms, but it can also be employed to shrink tumours that are resistant to surgery, microsatellite instability high, and help patients who have seen disease progression after chemotherapy."
Is Pembrolizumab a new or innovative treatment?
"Pembrolizumab was first trialled in 2010 at City of Hope. In the decade since, there have been 258 additional completed studies. There are presently 1000 active trials worldwide; a large number of these are based out of New york, New York."
In how many distinct places can participants take part in this research?
"Patients are being accepted at NYU Clinical Cancer Center (Site 3002) in New york, NY; Providence Saint John's Health Center (Site 3010) in Santa Monica, CA; University of Colorado Anschutz Cancer Pavilion (3012) in Aurora, CO; and 9 other locations."
Can new participants still join this research project?
"That is accurate. The clinical trial detailed on clinicaltrials.gov is looking for more participants and was originally posted on 6/26/2020. The listing was updated on 10/28/2022 and notes that 90 people are needed to participate at 9 different locations."
Does this research require participants to be of a certain age?
"The age requirements to participate in this clinical trial are that you must be over 18 years old but not a day over 120 years."
Who is this clinical trial meant for?
"This medical study is looking for 90 individuals who have a diagnosis of melanoma. To be eligible, participants must also meet the following requirements: histologically or cytologically confirmed Stage IIIB, IIIC, or IIID melanoma that is resectable and clinically detectable; no prior treatment for Stage IIIB, IIIC, or IIID melanoma; surgical resection of primary melanoma allowed; prior radiotherapy to the primary melanoma allowed; provided baseline tumor biopsy; male participants must use contraception during and after the intervention period if they are not abstinent from heterosexual intercourse; female participants cannot be pregnant or breastfeeding,"
Share this study with friends
Copy Link
Messenger